Kentucky Lung Cancer Research Program Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2004
NCT00378404
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (4)

1650-g vaccine (1 trial)

carboplatin (paraplatin) (1 trial)

gemcitabine (gemzar) (1 trial)

urea (1 trial)

Drugs in Phase 1 Trials (1)

docetaxel (taxotere) (1 trial)

Drugs in Other Trials (3)

bupropion (wellbutrin) (1 trial)

nicotine (nicorette) (1 trial)

varenicline (chantix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Pleural Effusion (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 8